Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human open-label dose-escalation and expansion study of GEN1046 in malignant solid tumors
MOH_2019-05-08_006011Phase 2Completed
- Sponsor
- Genmab
- Start
- Feb 2019
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of acasunlimab in Non-hematologic malignancy, non-small cell lung cancer (NSCLC), endometrial cancer (EC) and 4 more (4 arms), sponsored by Genmab. Primary endpoints: Antitumor activity of GEN1046 alone and in combination with docetaxel, Pharmacokinetic profile of GEN1046 and 2 more. Started Feb 2019; status: completed.
02
Drugs
acasunlimab
03
Conditions
Non-hematologic malignancynon-small cell lung cancer (NSCLC)endometrial cancer (EC)transitional cell carcinoma (TCC)triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on MOH_2019-05-08_006011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-05-08_006011.